MEDICINOVA INC (MNOV) Fundamental Analysis & Valuation

NASDAQ:MNOV • US58468P2065

Current stock price

1.38 USD
+0.01 (+0.73%)
Last:

This MNOV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. MNOV Profitability Analysis

1.1 Basic Checks

  • In the past year MNOV has reported negative net income.
  • MNOV had a negative operating cash flow in the past year.
  • MNOV had negative earnings in each of the past 5 years.
  • MNOV had a negative operating cash flow in each of the past 5 years.
MNOV Yearly Net Income VS EBIT VS OCF VS FCFMNOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • The Return On Assets of MNOV (-26.31%) is better than 68.74% of its industry peers.
  • MNOV's Return On Equity of -28.85% is fine compared to the rest of the industry. MNOV outperforms 76.31% of its industry peers.
Industry RankSector Rank
ROA -26.31%
ROE -28.85%
ROIC N/A
ROA(3y)-19.67%
ROA(5y)-17.91%
ROE(3y)-21.21%
ROE(5y)-19.16%
ROIC(3y)N/A
ROIC(5y)N/A
MNOV Yearly ROA, ROE, ROICMNOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30

1.3 Margins

  • MNOV has a Gross Margin of 7.59%. This is in the better half of the industry: MNOV outperforms 69.90% of its industry peers.
  • MNOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 7.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNOV Yearly Profit, Operating, Gross MarginsMNOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. MNOV Health Analysis

2.1 Basic Checks

  • MNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MNOV has been increased compared to 1 year ago.
  • Compared to 5 years ago, MNOV has more shares outstanding
  • MNOV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MNOV Yearly Shares OutstandingMNOV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
MNOV Yearly Total Debt VS Total AssetsMNOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -3.63, we must say that MNOV is in the distress zone and has some risk of bankruptcy.
  • MNOV has a Altman-Z score of -3.63. This is comparable to the rest of the industry: MNOV outperforms 42.14% of its industry peers.
  • MNOV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.63
ROIC/WACCN/A
WACC9.41%
MNOV Yearly LT Debt VS Equity VS FCFMNOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 8.16 indicates that MNOV has no problem at all paying its short term obligations.
  • MNOV has a better Current ratio (8.16) than 72.82% of its industry peers.
  • MNOV has a Quick Ratio of 8.16. This indicates that MNOV is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 8.16, MNOV is in the better half of the industry, outperforming 73.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.16
Quick Ratio 8.16
MNOV Yearly Current Assets VS Current LiabilitesMNOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. MNOV Growth Analysis

3.1 Past

  • MNOV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.35%.
EPS 1Y (TTM)-4.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 59.98% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, MNOV will show a very strong growth in Revenue. The Revenue will grow by 322.60% on average per year.
EPS Next Y-29.63%
EPS Next 2Y-30.38%
EPS Next 3Y15.29%
EPS Next 5Y59.98%
Revenue Next Year-16.67%
Revenue Next 2Y52.75%
Revenue Next 3Y557.78%
Revenue Next 5Y322.6%

3.3 Evolution

MNOV Yearly Revenue VS EstimatesMNOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
MNOV Yearly EPS VS EstimatesMNOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. MNOV Valuation Analysis

4.1 Price/Earnings Ratio

  • MNOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MNOV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNOV Price Earnings VS Forward Price EarningsMNOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNOV Per share dataMNOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MNOV's earnings are expected to grow with 15.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.38%
EPS Next 3Y15.29%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MNOV Dividend Analysis

5.1 Amount

  • No dividends for MNOV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MNOV Fundamentals: All Metrics, Ratios and Statistics

MEDICINOVA INC

NASDAQ:MNOV (4/27/2026, 12:42:51 PM)

1.38

+0.01 (+0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10
Earnings (Next)05-11
Inst Owners21.94%
Inst Owner Change0%
Ins Owners2.87%
Ins Owner Change0%
Market Cap67.92M
Revenue(TTM)409.70K
Net Income(TTM)-12.00M
Analysts82
Price Target9.18 (565.22%)
Short Float %0.42%
Short Ratio3.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.79%
Min EPS beat(2)41.18%
Max EPS beat(2)48.4%
EPS beat(4)4
Avg EPS beat(4)43.83%
Min EPS beat(4)27.76%
Max EPS beat(4)57.98%
EPS beat(8)6
Avg EPS beat(8)21.37%
EPS beat(12)10
Avg EPS beat(12)27.3%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10%
PT rev (3m)28.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)4.69%
EPS NY rev (3m)14.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 165.79
P/FCF N/A
P/OCF N/A
P/B 1.63
P/tB 2.5
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0.01
BVpS0.84
TBVpS0.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -26.31%
ROE -28.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 7.59%
FCFM N/A
ROA(3y)-19.67%
ROA(5y)-17.91%
ROE(3y)-21.21%
ROE(5y)-19.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.43%
Cap/Sales 0.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.16
Quick Ratio 8.16
Altman-Z -3.63
F-Score4
WACC9.41%
ROIC/WACCN/A
Cap/Depr(3y)41.21%
Cap/Depr(5y)54.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next Y-29.63%
EPS Next 2Y-30.38%
EPS Next 3Y15.29%
EPS Next 5Y59.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-16.67%
Revenue Next 2Y52.75%
Revenue Next 3Y557.78%
Revenue Next 5Y322.6%
EBIT growth 1Y-4.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.39%
EBIT Next 3Y36.8%
EBIT Next 5YN/A
FCF growth 1Y7.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.83%
OCF growth 3YN/A
OCF growth 5YN/A

MEDICINOVA INC / MNOV Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDICINOVA INC (MNOV) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MNOV.


What is the valuation status of MEDICINOVA INC (MNOV) stock?

ChartMill assigns a valuation rating of 0 / 10 to MEDICINOVA INC (MNOV). This can be considered as Overvalued.


What is the profitability of MNOV stock?

MEDICINOVA INC (MNOV) has a profitability rating of 2 / 10.


What is the earnings growth outlook for MEDICINOVA INC?

The Earnings per Share (EPS) of MEDICINOVA INC (MNOV) is expected to decline by -29.63% in the next year.